Skip to main content

Table 2 Dose-dependent reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 in adjuvant arthritis

From: Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis

Experiment 4

 

Arthritis score

Paw volume

Treatment

 

Day 19

Day 28

Day 19

Day 28

AA/PBS

 

--

--

--

--

AA/DxM-P

0.01 mg/kg

-10% ± 9.3%

+ 6% ± 11.9%

-18% ± 12.9%

-12% ± 8.4%

AA/DxM-P

0.1 mg/kg

-25% ± 6.9%

-4% ± 10.3%

-34% ± 10.1%

+ 9% ± 27.0%

AA/DxM-P

1.0 mg/kg

-69% ± 12.5% +

-27% ± 16.4%

-71% ± 10.4% +

-23% ± 16.0%

AA/liposomal DxM-P

0.01 mg/kg

-20% ± 14.0%

-13% ± 18.5%

-21% ± 21.1%

-5% ± 26.7%

AA/liposomal DxM-P

0.1 mg/kg

-38% ± 23.7%

-28% ± 16.9%

-44% ± 15.4%

-36% ± 12.2%

AA/liposomal DxM-P

1.0 mg/kg

-96% ± 2.0% ++ $$ § *

-59% ± 20.0%

-86% ± 5.1% ++ $$ §§

-58% ± 18.0%

  1. Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with free DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) or liposomal DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) compared to AA/PBS (Experiment 4 corresponds to the data in Figure 2).
  2. Data are expressed as means ± standard error of the mean.
  3. + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; $$ P ≤ 0.01 vs. AA/liposomal DxM-P 0.01 mg/kg; § P ≤ 0.05, §§ P ≤ 0.01 vs. AA/liposomal DxM-P 0.1 mg/kg; * P ≤ 0.05 vs. AA/DxM-P 1 mg/kg.